title: Chemotherapy of invasive thymoma.
abstract: Thirty-two patients with stage III or IV invasive thymoma (14 women and 18 men; median age, 40 years) were treated at the Padua Medical Oncology Department from 1977 to 1988. All patients received the following chemotherapy in 4-day courses: 50 mg/m2 of cisplatin intravenously (IV) and 40 mg/m2 of doxorubicin IV on day 1; 0.6 mg/m2 of vincristine IV on day 3; and 700 mg/m2 of cyclophosphamide IV on day 4 (ADOC). The courses were repeated every 3 weeks, and toxic effects were tolerable. The radiologically defined overall clinical response rate (complete plus partial response) was 91% with 47% clinical complete remissions; median time to progression was 11 months (range, 0 to 96) and the median estimated (Kaplan-Meier) progression-free interval was 22 months. Five of the 15 clinical complete remissions were pathologically confirmed at thoracotomy. We believe the ADOC regimen qualifies for adjuvant and preoperative treatment of invasive thymoma due to the high complete response and overall response rates.
authors.affiliation: Divisione di Oncologia Medica, Unità Locale Socio Sanitaria N. 21, Padova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Fornasiero
authors.forename: O
authors.initials: O
authors.lastname: Daniele
authors.forename: C
authors.initials: C
authors.lastname: Ghiotto
authors.forename: F
authors.initials: F
authors.lastname: Sartori
authors.forename: F
authors.initials: F
authors.lastname: Rea
authors.forename: M
authors.initials: M
authors.lastname: Piazza
authors.forename: L
authors.initials: L
authors.lastname: Fiore-Donati
authors.forename: P
authors.initials: P
authors.lastname: Morandi
authors.forename: S M
authors.initials: SM
authors.lastname: Aversa
authors.forename: A
authors.initials: A
authors.lastname: Paccagnella
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D011446:Prospective Studies; D012044:Regression Analysis; D012074:Remission Induction; D015996:Survival Rate; D013945:Thymoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin